NEU²

new drugs
against
neurological diseases

 
 

NEU² Partners: Evotec AG

Evotec AG

Manfred Eigen Campus
Essener Bogen 7
D22419 Hamburg

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology, inflammation and infectious diseases. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim and MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer’s disease. For additional information please go to www.evotec.com.

Ansprechpartner / Contact Person

Dr. Mark Gemkow
Tel: +49 40 56081-341
Fax: +49 40 56081-222
Email: mark.gemkow@evotec.com

Dr. Rainer Kuhn
T: +49 40 56081-241
F: +49 40 56081-222
Email: rainer.kuhn@evotec.com

Kontakt / Contact:

Zentrale / Main:
Evotec AG
Tel.: +49 40 56081 0
Fax: +49 40 56081 222
Email: info@evotec.com
URL: www.evotec.com